Company Description

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.

Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments.

The company was incorporated in 2007 and is headquartered in San Diego, California.

Organovo Holdings, Inc.

Country	United States
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	18
CEO	Keith E. Murphy

Contact Details

Address: 11555 Sorrento Valley Road, Suite 100 San Diego, California 92121 United States
Phone	858-224-1000
Website	organovo.com

Stock Details

Ticker Symbol	ONVO
Exchange	NASDAQ
Fiscal Year	April - March
Reporting Currency	USD
CIK Code	0001497253
CUSIP Number	68620A203
ISIN Number	US68620A2033
Employer ID	27-1488943
SIC Code	2836

Key Executives

Name	Position
Keith E. Murphy	Company Secretary and Executive Chairman
Vaidehi Joshi	Director of Discovery Biology and Director
Thomas P. Hess CPA, MBA	President and Chief Financial Officer
Dr. Curtis M. Tyree Ph.D.	Senior Vice President of Strategy and Business Development

Latest SEC Filings

Date	Type	Title
Apr 23, 2024	8-K	Current Report
Apr 12, 2024	S-1	General form for registration of securities under the Securities Act of 1933
Feb 12, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024	EFFECT	Notice of Effectiveness
Feb 8, 2024	424B5	Filing
Feb 8, 2024	10-Q	Quarterly Report
Feb 7, 2024	8-K	Current Report
Feb 5, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024	UPLOAD	Filing
Jan 26, 2024	S-3	Registration statement under Securities Act of 1933

View All SEC Filings